LumiraDx Stock Forecast, Price & News

LumiraDx (NASDAQ:LMDX) Frequently Asked Questions

Is LumiraDx a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LumiraDx stock.
View analyst ratings for LumiraDx or view top-rated stocks.

When is LumiraDx's next earnings date?

LumiraDx is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for LumiraDx.

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $109.08 million for the quarter, compared to analyst estimates of $100.84 million.
View LumiraDx's earnings history.

What price target have analysts set for LMDX?

3 Wall Street analysts have issued 12-month price objectives for LumiraDx's stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate LumiraDx's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price.
View analysts' price targets for LumiraDx or view top-rated stocks among Wall Street analysts.

Who are some of LumiraDx's key competitors?

Some companies that are related to LumiraDx include Daré Bioscience (DARE), Galectin Therapeutics (GALT), RedHill Biopharma (RDHL), Equillium (EQ), Xeris Pharmaceuticals (XERS), Oncternal Therapeutics (ONCT), Zynerba Pharmaceuticals (ZYNE), Vascular Biogenics (VBLT), OptiNose (OPTN), BioVie (BIVI), ProMetic Life Sciences (PFSCF), NuCana (NCNA), Enlivex Therapeutics (ENLV), Atreca (BCEL) and Palatin Technologies (PTN).
View all of LMDX's competitors.

What is LumiraDx's stock symbol?

LumiraDx trades on the NASDAQ under the ticker symbol "LMDX."

Who are LumiraDx's major shareholders?

LumiraDx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bill & Melinda Gates Foundation (152.67%), Senvest Management LLC (25.07%), Moore Capital Management LP (3.41%), Omni Partners US LLC (2.63%), Ionic Capital Management LLC (2.59%) and Caas Capital Management LP (1.40%).

Which institutional investors are buying LumiraDx stock?

LMDX stock was purchased by a variety of institutional investors in the last quarter, including Bill & Melinda Gates Foundation, Senvest Management LLC, Moore Capital Management LP, Omni Partners US LLC, Ionic Capital Management LLC, Caas Capital Management LP, Granby Capital Management LLC, and Citadel Advisors LLC.

How do I buy shares of LumiraDx?

Shares of LMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LumiraDx's stock price today?

One share of LMDX stock can currently be purchased for approximately $9.48.

How much money does LumiraDx make?

LumiraDx has a market capitalization of $34.61 million.

How many employees does LumiraDx have?

LumiraDx employs 2 workers across the globe.

Where are LumiraDx's headquarters?

LumiraDx is headquartered at 99 SUMMER STREET SUITE 200, BOSTON MA, 02110.

How can I contact LumiraDx?

LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The company can be reached via phone at 617-314-3901.